Gorsky Alex Insider Trading Activity

Average Profitability
20.98%
Insider Buys Quantity
1
Insider Buys Sum
$997,524.72
Insider Sells Quantity
1
Insider Sells Sum
$77.2M

Insider Activity of Gorsky Alex

Biography of Gorsky Alex

Gorsky Alex, born May 29, 1960, is a distinguished American business executive currently serving on the board of International Business Machines Corporation (IBM). Gorsky earned his Bachelor of Science degree from the U.S. Military Academy at West Point in 1982 and an MBA from The Wharton School of the University of Pennsylvania in 1996. His esteemed corporate journey commenced at Johnson & Johnson (J&J), where he joined as a sales representative in 1988. Over his three-decade tenure at J&J, Gorsky ascended through various strategic roles, achieving the apex of leadership as Chairman and CEO in 2012. He retired from the CEO position in 2021 but continued as Executive Chairman until January 2023. Under his leadership, J&J achieved significant growth and innovation, especially in its pharmaceutical division, bolstering its reputation as a healthcare giant. Known for his strategic vision and emphasis on ethical practices, Gorsky played a pivotal role in the development of groundbreaking medical treatments and technologies. His keen insights into operational efficiency and corporate governance have earned him respect beyond J&J, leading to his influential role at IBM. Throughout his career, Gorsky has received numerous accolades for his contributions to business and healthcare, including being named on Fortune's "World's Greatest Leaders" list. His efforts in advancing diversity and inclusion within corporate structures underline his commitment to creating an equitable workplace. At age 63, Gorsky continues to leverage his vast experience, providing strategic guidance to IBM, ensuring the company thrives in the expanding digital and technological landscape.

Disclaimer: This text is generated by a neural network based on open data from the Internet. In case of errors, please send an email to feedback@prismo.pro

2025-12-05PurchaseButterfly Network, Inc.
BFLY
200,000
0.0791%
$3.06$611,300+0.11%
2025-12-05PurchaseBiglari Holdings Inc.
BH
Chairman and CEO
1,465
0.0475%
$306.90$449,609-0.84%
2025-12-05SaleCytokinetics, Incorporated
CYTK
EVP, Chief Commercial Officer
52,486
0.0443%
$65.95$3.46M-0.42%
2025-12-05SaleDocuSign, Inc.
DOCU
director
363
0.0002%
$64.50$23,414+1.81%
2025-12-05SaleDominari Holdings Inc.
DOMH
COO
140,000
0.8589%
$3.82$534,254+1.94%
2025-12-05SaleDynatrace, Inc.
DT
director
253
<0.0001%
$44.24$11,193+0.47%
2025-12-05SaleDyne Therapeutics, Inc.
DYN
Chief Medical Officer
880
0.0006%
$20.72$18,234-2.12%
2025-12-05SaleDyne Therapeutics, Inc.
DYN
Chief Commercial Officer
144
0.0001%
$20.72$2,984-2.12%
2025-12-05SaleDyne Therapeutics, Inc.
DYN
CEO & President
2,662
0.0019%
$20.72$55,157-2.12%
2025-12-05SaleEnanta Pharmaceuticals, Inc.
ENTA
See Remarks
323
0.0015%
$14.23$4,596+2.6%
2025-12-05SaleEnanta Pharmaceuticals, Inc.
ENTA
See Remarks
542
0.0025%
$14.23$7,713+2.6%
2025-12-05SaleEnanta Pharmaceuticals, Inc.
ENTA
Chief Medical Officer
798
0.0036%
$14.23$11,356+2.6%
2025-12-05SaleEnanta Pharmaceuticals, Inc.
ENTA
Chief Product Strategy Officer
2,106
0.0096%
$14.23$29,968+2.6%
2025-12-05SaleEnanta Pharmaceuticals, Inc.
ENTA
Chief Business Officer
1,394
0.0064%
$14.23$19,837+2.6%
2025-12-05SaleEnanta Pharmaceuticals, Inc.
ENTA
Chief Scientific Officer
2,390
0.0109%
$14.23$34,010+2.6%
2025-12-05SaleEnanta Pharmaceuticals, Inc.
ENTA
President and CEO
4,743
0.0217%
$14.23$67,493+2.6%
2025-12-05SaleFennec Pharmaceuticals Inc.
FENC
director
10,000
0.0362%
$7.54$75,400+0.13%
2025-12-05SaleFive9, Inc.
FIVN
President
700
0.0009%
$20.53$14,371+0.58%
2025-12-05SaleFabrinet
FN
director
500
0.0014%
$482.11$241,057-0.76%
2025-12-05SaleIES Holdings, Inc.
IESC
Executive Chairman
3,774
0.0186%
$420.24$1.59M+1.99%
Total: 830495
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.